# US 2026/0083665 A1 · Implantable and biodegradable drug delivery devices and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083665 A1
- Document ID: US20260083665A1
- Status: Published application
- Kind: A1
- Application number: 19/400,815
- Filed: 2025-11-25
- Published: 2026-03-26
- Earliest claimed: 2021-11-17
- Assignees: PanTher Therapeutics, Inc.
- Applicants: PanTher Therapeutics, Inc.
- Inventors: Laura INDOLFI; Margaret LASHOF-SULLIVAN
- Web page: https://patentgrep.com/patent/US20260083665A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are implantable and biodegradable drug delivery devices capable of delivering an active pharmaceutical ingredient (API) directly to a target tissue site. The drug delivery devices can include at least two layers. One of the layers can include the API and a biodegradable polymer and a second layer can include another biodegradable polymer that degrades slower than the first biodegradable polymer. When the device is placed directly on the target tissue, the API layer can degrade thereby releasing the API towards the target tissue while the non-API layer can prevent the API from being released away from the target tissue onto non-target tissue.

## Claims

### Claim 1

A drug delivery device for in vivo placement, comprising:
a first layer comprising an active pharmaceutical ingredient (API) and a first poly(lactic-co-glycolic acid) (PLGA) having a lactic acid to glycolic acid ratio of between 50:50 and 65:35; and
a second layer on a first side of the first layer, the second layer comprising a second PLGA having a lactic acid to glycolic acid ratio of between 70:30 and 80:20;
wherein the second layer does not comprise the API and the second layer has a slower degradation rate than the first layer in an aqueous environment at 37° C.;
wherein less than 20% of the API is released from the first layer after one week in an aqueous environment at 37° C.; and
wherein the first layer is fully degraded within six weeks in an aqueous environment at 37° C.

### Claim 2 (depends on 1)

The drug delivery device of claim 1, wherein the device has a total thickness of 100-1500 microns.

### Claim 3 (depends on 2)

The drug delivery device of claim 2, wherein each of the first and second layers is 100-300 microns in thickness.

### Claim 4 (depends on 1)

The drug delivery device of claim 1, wherein the first layer comprises at least 2 wt % solvent.

### Claim 5 (depends on 4)

The drug delivery device of claim 4, wherein the second layer comprises at least 2 wt. % solvent.

### Claim 6 (depends on 5)

The drug delivery device of claim 5, wherein the solvent in the first and second layers is acetone.

### Claim 7 (depends on 1)

The drug delivery device of claim 1, wherein less than 20% of the API is released from the first layer after two weeks in an aqueous environment at 37° C.

### Claim 8 (depends on 1)

The drug delivery device of claim 1, wherein the first layer comprises at least 5 wt % of the API.

### Claim 9 (depends on 8)

The drug delivery device of claim 8, wherein the API is paclitaxel.

### Claim 10 (depends on 1)

The drug delivery device of claim 1, wherein the first PLGA has a lactic acid to glycolic acid ratio of about 50:50.

### Claim 11 (depends on 1)

The drug delivery device of claim 1, wherein the second PLGA has a lactic acid to glycolic acid ratio of 75:25.

### Claim 12 (depends on 1)

The drug delivery device of claim 1, wherein the API is released from the first layer at a substantially linear release rate after one week in an aqueous environment at 37° C.

### Claim 13 (depends on 1)

The drug delivery device of claim 1, wherein an outer perimeter of the first layer is inset relative to an outer perimeter of the second layer such that a portion of the second layer extends beyond the first layer.

### Claim 14 (depends on 1)

The drug delivery device of claim 1, wherein the first layer comprises 60-300 mg of the API.

### Claim 15 (depends on 14)

The drug delivery device of claim 14, wherein the first layer comprises 80-150 mg of the API.

### Claim 16 (depends on 1)

The drug delivery device of claim 1, further comprising a third layer comprising the API and PLGA, the third layer on a second side of the first layer.

### Claim 17 (depends on 16)

The drug delivery device of claim 16, further comprising a fourth layer comprising the API and PLGA, the fourth layer on a side of the third layer.

### Claim 18 (depends on 17)

The drug delivery device of claim 17, wherein the API is paclitaxel.

### Claim 19 (depends on 18)

The drug delivery device of claim 18, wherein each of the first, second, third, and fourth layers comprise at least 100 mg of the API, and the API comprises paclitaxel.

### Claim 20 (depends on 1)

The drug delivery device of claim 1, wherein the second layer is fully degraded within twelve weeks in an aqueous environment at 37° C.
